Langkau ke kandungan utama

Treatment of heart valve disease during pregnancy

Heart valve disease constitutes the majority of all causes of heart disease during pregnancy. Women with heart valve disease are vulnerable to deterioration with subsequent increased risk of maternal and fetal morbidity and mortality.

The optimal treatment is indecisive; on one hand medical treatment might relieve symptoms but causes hypoxia and have adverse effects on the developing fetus, while interventional therapy might increase the risk of maternal and fetal complications. No randomised controlled trials addressing the optimal treatment have been performed. Therefore, there is insufficient evidence to define the optimal treatment of heart valve disease during pregnancy. 

Additional. Observational studies are the only available information on this subject. This implies a selection bias; case series with reasonable outcome might be reported more frequent than those with poor outcome. Although observational studies might imply a selection bias, these studies are the best available evidence in adverse maternal and neonatal effects and are described in detail.

Latar Belakang

Valvular heart disease constitutes the majority of all causes of heart disease in pregnancy. In the presence of valvular heart disease, the necessary haemodynamic changes of pregnancy might cause heart failure, leading to severe maternal and fetal morbidity and even mortality. Treatment of valvular heart disease is indicated when patients experience a deterioration of symptoms and in case of a severe valvular lesion. Whether medical therapy or interventional therapy is the optimal treatment for both mother and child is unclear.

Matlamat

To assess effectiveness and adverse effects of the different treatment modalities of valvular heart disease in pregnancy to improve maternal and neonatal outcomes.

Kaedah Pencarian

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2011), EMBASE (1980 to 23 March 2011) and the reference lists of background review articles.

Kriteria Pemilihan

Randomised controlled trials, quasi-randomised controlled and cluster-randomised controlled trials comparing medical therapy with percutaneous or surgical intervention for the treatment of valvular heart disease in pregnancy.

Pengumpulan Data dan Analisis

We identified no (randomised) controlled trials to assess the effectiveness and adverse effects of the treatment of valvular heart disease in pregnancy.

Keputusan Utama

There were no randomised controlled trials, quasi-randomised controlled trials or cluster-randomised trials identified from the search strategy.

Kesimpulan Pengarang

There is insufficient evidence to define the most effective treatment of valvular heart disease in pregnancy to improve maternal and neonatal outcomes.

Petikan
Henriquez DDCA, Roos-Hesselink JW, Schalij MJ, Klautz RJM, Helmerhorst FM, de Groot CJM. Treatment of valvular heart disease during pregnancy for improving maternal and neonatal outcome. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD008128. DOI: 10.1002/14651858.CD008128.pub2.

Penggunaan cookie kami

Kami menggunakan cookie yang diperlukan untuk menjadikan laman web kami berfungsi. Kami juga ingin menetapkan cookie analitik pilihan untuk membantu kami memperbaikinya. Kami tidak akan menetapkan cookie pilihan melainkan anda mengaktifkannya. Menggunakan alat ini akan menetapkan cookie pada peranti anda untuk mengingati pilihan anda. Anda boleh menukar pilihan cookie anda pada bila-bila masa dengan menekan pautan 'Tetapan cookie' di bahagian bawah setiap halaman.
Untuk maklumat lebih terperinci mengenai cookie yang kami gunakan, lihat halaman halaman cookie.

Terima semua
Konfigurasikan